沙利度胺联合奥沙利铂和卡培他滨治疗转移性结肠癌的疗效观察  

Efficacy of thalidomide combined with oxaliplatin and capecitabine in the treatment of metastatic colorectal cancer

作　　者：黄文金[1] 邱子丹 郑俊琼[1] HUANG Wen-jin;QIU Zi-dan;ZHENG Jun-qiong(Department of Oncology,Longyan First Hospital,Longyan 364000,China)

机构地区：[1]福建省龙岩市第一医院肿瘤内科,龙岩364000

出　　处：《中国肿瘤临床与康复》2020年第7期853-855,共3页Chinese Journal of Clinical Oncology and Rehabilitation

摘　　要：目的探讨沙利度胺联合奥沙利铂和卡培他滨(XELOX方案)治疗转移性结肠癌的疗效。方法选取2015年11月至2017年11月间福建省龙岩市第一医院收治的80例转移性结肠癌患者的资料进行回顾性分析。根据治疗方法不同进行分组,仅采用XELOX化疗方案治疗的40例患者纳入对照组,采用XELOX化疗方案联合沙利度胺治疗的40例患者纳入观察组。比较两组患者的近期治疗效果和生存时间。结果观察组治疗有效率为42. 5%,优于对照组的20. 0%,差异有统计学意义(P <0. 05)。观察组的总生存时间中位数为20. 97个月,高于对照组的16. 99个月,差异有统计学意义(P <0. 05)。结论对转移性结肠癌患者采用沙利度胺联合XELOX的治疗方案,有助于提升患者近期治疗效果,延长生存时间。Objective To explore the efficacy of thalidomide combined with oxaliplatin and capecitabine( XELOX regimen) in the treatment of metastatic colorectal cancer. Methods A retrospective analysis of 80 patients with metastatic colon cancer was performed at Longyan First Hospital from November2015 to November 2017. Based on the treatment they received,they were divided into two groups. Forty patients who received thalidomide combined with XELOX were included in an observation group and 40 patients who received were included in a control group. Short-term efficacy and survival time were compared between the two groups. Result The treatment efficacy was 42. 5% in the observation group which was higher than 20. 0% of the control group( P < 0. 05). The median overall survival time was 20. 972 months in the observation group,which was higher than 16. 99 months in the control group( P < 0. 05). Conclusion The use of thalidomide combined with XELOX helps to improve the efficacy of short-term treatment efficay,and prolong survival time in patients with metastatic colorectal cancer.

关 键 词：沙利度胺 转移性结肠肿瘤 消化系统 恶性肿瘤 癌细胞 

分 类 号：R735.3[医药卫生—肿瘤]